Head-to-head evidence
BMS-986322 vs CMS-D001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
BMS-986322
Developed by Bristol-Myers Squibb and partners
NCT05730725 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.
CMS-D001
Developed by Dermavon Holdings
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2028 · NCT07432854 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BMS-986322's landscape · CMS-D001's landscape